Re-reading ACT, BCG, and Low COVID-19 in Africa.

Autor: Kangbai JB; Center for International Health, University of Munich (LMU), Munich, Germany.; Department of Environmental Health Sciences, Njala University, Freetown, Sierra Leone.; The National COVID Emergency Response Centre (NACOVERC), Freetown, Sierra Leone., Babawo LS; The National COVID Emergency Response Centre (NACOVERC), Freetown, Sierra Leone.; Department of Nursing, Njala University, Freetown, Sierra Leone., Kaitibi D; Njala University, Freetown, Sierra Leone., Sandi AA; Ministry of Health and Sanitation, Freetown, Sierra Leone., George AM; Department of Nursing, Njala University, Freetown, Sierra Leone., Sahr F; The National COVID Emergency Response Centre (NACOVERC), Freetown, Sierra Leone.; Department of Microbiology, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone.; The 34 Military Hospital, Wilberforce, Freetown, Sierra Leone.
Jazyk: angličtina
Zdroj: SN comprehensive clinical medicine [SN Compr Clin Med] 2021; Vol. 3 (1), pp. 11-15. Date of Electronic Publication: 2021 Jan 12.
DOI: 10.1007/s42399-020-00704-3
Abstrakt: October 11, 2020, marks the seventh month since the World Health Organization (WHO) officially declared COVID-19 a pandemic. Unlike other coronavirus diseases, there is a geographically disproportionate distribution of the incidence of COVID-19 cases around the world. We observed a significantly high COVID-19 cases and deaths in countries and territories with no or very small number of malaria cases or no or low national TB cases in 2018. We speculate that the high incidence of COVID-19 cases and deaths in countries less affected by malaria is partly due to overexposure to malaria which led to the regular use of the artemisinin anti-malaria drugs as well as the regular use of bacillus Calmette-Guérin (BCG) vaccine for TB prevention. The vaccine produced an almost life-long immunity to TB and meningitis to its recipients. We are thus calling for a COVID-19 containment and clinical management protocol that will incorporate the use of the anti-malaria ACT drug cocktail and BCG vaccine on compassionate ground.
Competing Interests: Competing InterestsAll authors declare they have no competing interest.
(© The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2021.)
Databáze: MEDLINE
Externí odkaz: